Breaking News Updates for the Psychedelics Industry

Psychedelics News

Breaking News

Breaking News, Industry

9 Aug 2023

atai Life Sciences Announces Results of New Phase 1 Study of PCN-101 (R-Ketamine)

Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine)....

By Microdose NewsDesk

Breaking News, Finance

1 Aug 2023

Raising Capital: Cybin Announces Public Offering

Cybin has announced a public offering for gross proceeds of US$8,250,000....

By Microdose NewsDesk

Breaking News

20 Jul 2023

Filament Health Heading to NASDAQ With SPAC Merger

The agreement would merge Filament with Jupiter Acquisition Corporation (NASDAQ: JAQC)...

By Microdose NewsDesk

Breaking News, Science

17 Jul 2023

Positive Data From COMPASS Pathways’ Phase 2 Trial Combining Psilocybin & SSRIs

Results of COMPASS Pathways’ study suggests that SSRIs do not interfere with the potential therapeutic effect of COMP360...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Industry

22 Jun 2023

MindMed Survives Takeover Attempt: Shareholders Reject FCM Board Candidates

MindMed shareholders have voted to elect all 6 of the company’s proposed board members — rejecting the candidates from activist investors....

By Jason Najum

Breaking News

21 Jun 2023

Breaking News: Toms Shoes Founder Pledges $100 million for Psychedelic Research

Blake Mycoskie, founder of Toms Shoes, has pledged to give $100 million to support psychedelic research and access...

By Microdose NewsDesk

Breaking News

20 Jun 2023

PharmaTher and Vitruvias Enter Into Commercialization Agreement for KETARX™ in the US

Pharmather has announced a collaboration agreement with Vitruvias Therapeutics for the commercialization of its KETARX (racemic ketamine) products in the U.S....

By Microdose NewsDesk

Breaking News

1 Jun 2023

Breaking News: Reunion Neuroscience Sold and Going Private

This morning we received news that Reunion Neuroscience has been sold to MPM BioImpact, a private biotechnology investment firm....

By Microdose NewsDesk

Breaking News

31 May 2023

Breaking News: Kentucky Commits $42 Million for Psychedelic Research

Attorney General for the US State of Kentucky, Daniel Cameron, announced that Kentucky will allocate $42 million for psychedelic research, specifically ibogaine for opioid addiction....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result